Figure 4.

A representative patient from the minocycline 3% arm, at baseline and at week 12; the inflammatory lesion count for the patient decreased from 21 lesions at baseline to one lesion at week 12, and the Investigator's Global Assessment score increased from 3 at baseline to 1 at week 12.